Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)

Historic Total Current Liabilities for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $7.0 million.

  • Benitec Biopharma's Total Current Liabilities rose 10442.25% to $7.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.0 million, marking a year-over-year increase of 10442.25%. This contributed to the annual value of $4.9 million for FY2024, which is 2378.08% up from last year.
  • According to the latest figures from Q1 2025, Benitec Biopharma's Total Current Liabilities is $7.0 million, which was up 10442.25% from $3.1 million recorded in Q4 2024.
  • Benitec Biopharma's Total Current Liabilities' 5-year high stood at $7.0 million during Q1 2025, with a 5-year trough of $1.4 million in Q2 2021.
  • In the last 5 years, Benitec Biopharma's Total Current Liabilities had a median value of $3.1 million in 2024 and averaged $3.4 million.
  • Per our database at Business Quant, Benitec Biopharma's Total Current Liabilities surged by 21835.69% in 2021 and then tumbled by 4624.09% in 2024.
  • Benitec Biopharma's Total Current Liabilities (Quarter) stood at $2.5 million in 2021, then increased by 0.36% to $2.5 million in 2022, then soared by 130.86% to $5.7 million in 2023, then plummeted by 46.24% to $3.1 million in 2024, then soared by 127.45% to $7.0 million in 2025.
  • Its Total Current Liabilities was $7.0 million in Q1 2025, compared to $3.1 million in Q4 2024 and $4.6 million in Q3 2024.